DOACs

Unlike warfarin, DOACs need no routine INR monitoring and have fewer food interactions — but that convenience comes with a critical catch when the patient is actively bleeding.

Direct oral anticoagulants — rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and dabigatran (Pradaxa) — work by directly inhibiting a single clotting factor without needing antithrombin III as a cofactor. Dabigatran is a direct thrombin (factor IIa) inhibitor; the others are direct factor Xa inhibitors. This targeted mechanism produces a predictable, dose-dependent anticoagulant effect, which is why routine coagulation monitoring (PT/INR, aPTT) is not required. Indications include stroke prevention in nonvalvular atrial fibrillation, DVT/PE treatment and prophylaxis, and post-surgical thromboprophylaxis. DOACs have rapid onset (1–4 hours) and shorter half-lives (5–17 hours depending on agent) compared to warfarin's delayed onset and long half-life. Renal function matters: all DOACs have some degree of renal clearance, with dabigatran being the most renally dependent (~80%). Creatinine clearance must be assessed before initiation and periodically thereafter. For active, life-threatening bleeding, specific reversal agents exist: idarucizumab (Praxbind) reverses dabigatran; andexanet alfa (Andexxa) reverses factor Xa inhibitors (rivaroxaban, apixaban, edoxaban).

Key Distinctions

Don't confuse DOACs with warfarin — DOACs require no INR monitoring, have no significant vitamin K dietary restrictions, and have specific reversal agents rather than vitamin K/FFP. Students often think all anticoagulants need routine lab monitoring; DOACs do not. Dabigatran is the only direct thrombin inhibitor in the group — the rest target factor Xa. Dabigatran requires renal dose adjustment or avoidance at CrCl <30 mL/min more strictly than Xa inhibitors.

Clinical Pearl

No INR, no problem — until the patient bleeds. Know the reversal agent: idarucizumab for dabigatran, andexanet alfa for the Xa inhibitors. Match the drug to its antidote.